Resveratrol improves treatment outcome and laboratory parameters in patients with Takayasu arteritis: A randomized double-blind and placebo-controlled trial

Abstract Tumor necrosis factor (TNF) inhibitors have exhibited certain clinical efficacy in treating refractory Takayasu arteritis (TA), albeit with severe adverse effects. We aimed to explore the anti-TNF function of resveratrol, a natural compound, in the treatment of TA. A total of 271 patients d...

Full description

Saved in:
Bibliographic Details
Published in:Immunobiology (1979) 2017-02, Vol.222 (2), p.164-168
Main Authors: Shi, Guoxun, Hua, Minhui, Xu, Qiangwei, Ren, Tianli
Format: Article
Language:English
Subjects:
Adolescent
Adult
Advanced Basic Science
Allergy and Immunology
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Biomarkers
Blood Sedimentation
C-Reactive Protein
Erythrocyte sedimentation rate
Female
Humans
Male
Middle Aged
Resveratrol
Stilbenes - pharmacology
Stilbenes - therapeutic use
Takayasu arteritis
Takayasu Arteritis - diagnosis
Takayasu Arteritis - drug therapy
Takayasu Arteritis - metabolism
Treatment Outcome
Tumor necrosis factor
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - blood
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Tumor necrosis factor (TNF) inhibitors have exhibited certain clinical efficacy in treating refractory Takayasu arteritis (TA), albeit with severe adverse effects. We aimed to explore the anti-TNF function of resveratrol, a natural compound, in the treatment of TA. A total of 271 patients diagnosed of acute TA were enrolled in this clinical trial, who were then randomized to be administered 250 mg resveratrol or placebo on a daily basis for a period of 3 months, and revisited biweekly to assess treatment outcomes. Primary treatment outcome was defined as the disease activity, determined using the Birmingham Vascular Activity Score (BVAS). Secondary outcome was defined by laboratory parameters, including erythrocyte sedimentation rate (ESR), plasma levels of C-reactive protein (CRP) and TNF-α. BVAS score and laboratory parameters of patients receiving resveratrol treatment exhibited a steady decline throughout the study. In contrast, outcomes remained practically unchanged in placebo-treated patients. Strong linear correlations were also observed between TNF-α with BVAS scores, ESR and plasma levels of CRP. Resveratrol could greatly improve treatment outcome and laboratory parameters in acute TA patients, likely due to its anti-TNF property.
ISSN:0171-2985
1878-3279
DOI:10.1016/j.imbio.2016.10.008